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SUMMARY
Background
Nonsteroidal anti-inflammatory drugs are associated with gastrointestinal (GI)
damage. The Celecoxib vs. Omeprazole and Diclofenac for At-Risk Osteoarthritis
and Rheumatoid Arthritis Patients (CONDOR) trial showed that a haemoglobin
drop  2 g/dL adjudicated as either of defined or presumed GI origin was the
most frequent component/event for the composite GI primary end point. This
adverse event is potentially clinically relevant in long-term NSAID treatment.
Aim
To define potential risk factors associated with a decrease in haemoglobin/haematocrit.
Methods
Post hoc analysis of the CONDOR trial was conducted in the intention-to-treat
population. Clinically significant blood loss was defined as: (i) a haemoglobin drop
 2 g/dL and/or a haematocrit drop  10%; and (ii) blood loss adjudicated as
either of defined or presumed GI origin. Fifteen risk factors were evaluated by
stepwise logistic regression. Each factor had to be significant at <0.20 a to be
included in the model.
Results
A total of 64/3774 (1.7%) osteoarthritis (OA) patients had decreased haemoglobin/
haematocrit and were adjudicated to the GI endpoint. Significant risk factors, at
the 0.20 a level found to be associated with clinically significant blood loss in OA
patients included [odds ratio (80% CI)] baseline C-reactive protein (CRP) levels
[2.27 (1.46–3.53)], history of gastritis and history of GI intolerance [1.55 (1.06–
2.28)], positive Helicobacter pylori at screening [1.54 (1.07–2.22)], increasing age
[1.17 (1.04–1.32)] and body mass index [BMI; 1.03 (1.00–1.06)].
Conclusions
Monitoring for decreases in haemoglobin should be considered for all OA patients
and especially those with an increased age, BMI, history of gastritis and GI intoler-
ance, CRP levels >1 mg/dL and/or positive H. pylori status, as this may affect their
clinical management.
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INTRODUCTION
Nonselective nonsteroidal anti-inflammatory drugs
(NSAIDs) plus a proton pump inhibitor (PPI) or cyclo-
oxygenase (COX)-2 selective NSAIDs are similarly effec-
tive in reducing the risk of upper gastrointestinal (GI)
events in patients at high GI risk.1 With average cardio-
vascular (CV) risk, current guidelines recommend the
use of a COX-2-selective NSAID for patients at GI risk
who need NSAIDs.2 However, there is strong evidence
suggesting that all NSAIDs are associated with damage
in the upper and lower GI tracts. The intestinal damage
associated with the use of NSAIDs includes the develop-
ment of increased mucosal permeability, inflammation,
erosions, ulcers, malabsorption, strictures, perforation
and blood loss that can be either acute or chronic in nat-
ure and with/without identified mucosal lesions.3
A decrease in haemoglobin of  2 g/dL has previously
been suggested as a clinically relevant marker of mucosal
damage4 and has been evaluated as an end point of clini-
cal interest in several GI outcome studies.5–8 While the
clinical relevance of a  2 g/dL decrease in haemoglobin
is currently the subject of active debate,3 this measure-
ment serves as a potential marker of NSAID damage
throughout the entire GI tract.
In two large scale, independent randomised controlled
outcome trials [Celecoxib vs. Omeprazole and Diclofenac
for At-Risk Osteoarthritis and Rheumatoid Arthritis
Patients (CONDOR)1 and Celecoxib Long-term Arthritis
Safety Study (CLASS) (non-aspirin using sub-popula-
tion)9], clinically significant decreases in haemoglobin
occurred, in non-aspirin using patients, in a similar fash-
ion over time despite differences in trial design.10 These
findings support the clinical reproducibility of this out-
come, related to continuous long-term NSAID treatment.
The CONDOR trial1 showed that independent of the
use of a PPI, both COX-2 selective NSAIDs and nonse-
lective NSAIDs were associated with clinically significant
blood loss, predefined as decreases in haemoglobin
 2 g/dL and/or haematocrit drop  10%. In fact, the
decrease in haemoglobin  2 g/dL adjudicated as of
defined GI origin or presumed GI origin was found to
be the main component of the composite primary GI
end point in the CONDOR trial (92 of 101 predefined
Clinically Significant Upper and Lower GI Events). We
considered it important to define the risk factors for this
component of the primary outcome, clinically significant
blood loss, since it may be relevant for the management
of patients treated with NSAIDs in clinical practice.
Therefore, a post hoc analysis of data from the CON-
DOR trial was conducted to identify potential risk
factors for a clinically significant blood loss, defined as:
(i) a haemoglobin drop  2 g/dL and/or a haematocrit
drop  10%; and (ii) blood loss adjudicated as either of
defined or presumed GI origin.
MATERIALS AND METHODS
This was a post hoc analysis of the CONDOR trial in
which clinically significant blood loss was investigated.
Clinically significant blood loss was predefined in the
CONDOR trial as: (i) haemoglobin drop  2 g/dL and/
or a haematocrit drop  10%; and (ii) blood loss was
adjudicated as either defined or presumed GI origin,
based on all the available clinical data. This same defini-
tion is used in this analysis.
The CONDOR trial (NCT00141102) was a double-
blind, parallel-group, multicentre, international trial that
randomised a total of 4484 patients to receive either oral
celecoxib 200 mg twice a day or diclofenac slow release
(SR) 75 mg twice a day plus omeprazole 20 mg once a
day for 6 months. Patients had osteoarthritis (OA) and/
or rheumatoid arthritis (RA) with a high risk of GI
adverse events, were Helicobacter pylori negative and
were not allowed to use aspirin. A detailed description of
the study design has been published previously.1, 3
Members of an independent, blinded adjudication
committee (FKLC, JG, AL, JS) determined whether the
primary end point was attained according to the prede-
fined criteria in the primary analysis of the CONDOR
data.1 The GI event was adjudicated as clinically signifi-
cant blood loss of defined GI origin when the bleeding
source was identified. Without a defined source, if there
was no clinical or laboratory evidence of a non-GI
source of blood loss, the event was adjudicated as clini-
cally significant blood loss of presumed occult GI origin,
including possible small-bowel blood loss.
Data analysis
From the collected baseline data, 15 potentially relevant
risk factors for the clinically significant blood loss in
OA/RA patients were identified based on previous stud-
ies demonstrating risk factors for upper GI events11, 12
and lower GI tract (increasing age and prior lower GI
event) of NSAID users.13, 14 Potential demographic risk
factors included increased age (continuous variable), race
(white, black, Asian, Hispanic, other), and gender
(female vs. male). The risk factors found to be relevant
in the medical history included H. pylori status at
screening (positive vs. negative testing based on local
standards per protocol), primary diagnosis (RA vs. OA),
history of upper GI complications (yes vs. no), history of
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gastritis and GI intolerance (yes vs. no), prior PPI use
within 6 months of randomisation (yes vs. no), alcohol
consumption (did not drink vs. drank), body mass index
(BMI; continuous variable), documented history of lower
GI disorders (ulcerative colitis, Crohn’s disease, small-
bowel perforation, large-bowel perforation, small-bowel
obstruction, large-bowel obstruction, bowel carcinoma,
and/or haemorrhoids) (yes or no), prior steroid use
within 6 months of randomisation (yes vs. no) and
patient-reported history of anaemia (yes vs. no). Poten-
tially relevant baseline laboratory data included baseline
haemoglobin (g/dL; continuous variable) and baseline
C-reactive protein (CRP) level (>1 vs.  1 mg/dL).
Analysis was conducted in the intention-to-treat (ITT)
population, including all patients randomly allocated to
treatment.1 In CONDOR, patients treated with celecoxib
had fewer haemoglobin drops than patients treated with
diclofenac SR plus omeprazole (15 vs. 77 patients)1; how-
ever, as there were only 15 events in the celecoxib arm,
an independent analysis of risk factors for a  2 g/dL
haemoglobin drop by study arm was not feasible.
A descriptive statistical summary of the data was first
conducted and presented by the binary response variable.
To evaluate the potentially relevant risk factors, a step-
wise logistic regression model with adjustment for treat-
ment was used. Each risk factor had to be statistically
significant at 0.20 a level to be included as a risk factor
during the selection process and in the final model.15
Odds ratios, 80% CIs and associated P values (v2 test-
ing) for the potentially relevant risk factors identified
were calculated. The significance was taken to higher level
(P < 0.20, 80% CI level) as the CONDOR trial was not
designed and not powered for testing these risk factors.
In a preliminary analysis, the OA/RA cohort was first
analysed with the inclusion of both baseline haemoglobin
value and primary diagnosis (OA vs. RA) in the model.
However, as a result of the observation of a low correla-
tion between baseline haemoglobin level and haemoglo-
bin change from baseline (ρ = 0.27), the baseline
haemoglobin level was removed from the logistic regres-
sion model. Steroid use was also determined to be a con-
founding factor due to an imbalance in steroid use
within the RA population. To avoid this confounding
factor and to provide a clearer understanding of the risk
factors associated with a decrease in haemoglobin/
haematocrit in OA patients, further analyses were carried
out on the OA population only, who comprised the
majority of patients in CONDOR (3774/4484). The lim-
ited number of patients with RA in the study prevented
reliable analysis of risk factors for this subset of patients.
RESULTS
A total of 136/4484 OA and RA patients in the ITT pop-
ulation had a  2 g/dL decrease in haemoglobin and/or
 10% decrease in haematocrit and the events were sent
for adjudication. Of these 136 OA/RA patients, 92 were
adjudicated as having ‘Clinically Significant Upper and
Lower GI Events’ (Figure 1).
The final risk factors included in the model were:
baseline CRP levels (>1 mg/dL vs.  1 mg/dL); positive
H. pylori at screening (yes vs. no); age; history of gastritis
and GI intolerance (yes vs. no), BMI, race, gender, prior
PPI use, alcohol consumption, history of upper GI com-
plications, history of lower GI disorders and history of
anaemia.
N = 4484
(OA = 3774/RA = 710)
Patients sent for adjudication
n = 253
(OA = 195/RA = 58)
Clinically significant upper




and lower GI events
(OA = 64/RA = 28)
NoYes
n = 44
and lower GI events
(OA = 39/RA = 5)
Hgb/Hct drop with no
clinically significant upper
n = 136
Hgb/Hct drop based on laboratory values
(OA = 103/RA = 33)
and sent for adjudication
Figure 1 | Flow diagram of patients with OA/RA
referred for adjudication for a decrease in haemoglobin
 2 g/dL and/or haematocrit  10% from baseline.
Clinically significant upper and lower GI events defined
as a composite of clinically significant events occurring
throughout the GI tract. Components were
gastroduodenal, small-bowel or large-bowel
haemorrhage; gastric-outlet obstruction;
gastroduodenal, small-bowel or large-bowel perforation;
clinically significant anaemia of defined GI or presumed
occult GI origin (including possible blood loss from the
small bowel) and acute GI haemorrhage of unknown
origin (including presumed small-bowel haemorrhage).
Clinically significant anaemia was defined as a
decrease in haemoglobin of  2 g/dL, or a decrease in
haematocrit of  10%.
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The baseline characteristics for the OA patients are
shown in Table 1. A total of 3774 patients were analysed
in the OA cohort. Of these patients, 64 had a  2 g/dL
decrease in haemoglobin and/or  10% decrease in hae-
matocrit adjudicated as a ‘Clinically Significant Upper
and Lower GI Event.’ The logistic regression analysis in
the OA cohort showed the significant risk factors, at the
0.20 a level, for clinically significant blood loss were:
baseline CRP levels (>1 mg/dL vs.  1 mg/dL); positive
H. pylori at screening (yes vs. no); age; history of gastritis
and history of GI intolerance (yes vs. no) and BMI for
Table 1 | Descriptive summary of baseline
demographics, medical history and laboratory values
for OA patients in the CONDOR trial
 2 g/dL decrease in Hgb
and/or  10% decrease in
Hct and confirmed cases
(N = 3774)
Yes No








White 35 (54.69) 2172 (58.54)
Black 2 (3.13) 96 (2.59)
Asian 5 (7.81) 363 (9.78)
Other 4 (6.25) 333 (8.98)
Hispanic 18 (28.13) 746 (20.11)
Gender
Female 55 (85.94) 3068 (82.70)
Male 9 (14.06) 642 (17.30)
Medical history
Helicobacter pylori status at screening
Negative 46 (71.88) 2967 (79.97)
Positive 18 (28.13) 743 (20.03)
History of upper GI complications
No 54 (84.38) 3102 (83.61)
Yes 10 (15.63) 608 (16.39)
History of gastritis and GI intolerance
No 49 (76.56) 3097 (83.48)
Yes 15 (23.44) 613 (16.52)
Prior PPI use within 6 months of randomisation
No 53 (82.81) 3137 (84.56)
Yes 11 (17.19) 573 (15.44)
Alcohol consumption
Did not drink 56 (87.50) 2995 (80.73)
Drank 8 (12.50) 715 (19.27)
BMI (continuous variable)
N 64 3697
Mean (s.d.) 30.1 (6.37) 29.1 (5.20)
Median 28.2 28.4
Range 20.3–48.4 14.1–70.0
History of lower GI disorders
No 58 (90.63) 3414 (92.02)
Yes 6 (9.38) 296 (7.98)
Prior steroid use within 6 months of randomisation
No 64 (100) 3683 (99.27)
Yes 0 27 (0.73)
History of patient-reported
anaemia
No 63 (98.44) 3598 (96.98)
Yes 1 (1.56) 112 (3.02)
Table 1 | (Continued)
 2 g/dL decrease in Hgb
and/or  10% decrease in
Hct and confirmed cases
(N = 3774)
Yes No









 1 mg/dL 53 (82.81) 3397 (92.06)
>1 mg/dL 11 (17.19) 293 (7.94)
Values are n (%) unless otherwise specified.
Table 2 | Risk factors for clinically significant
decreases in haemoglobin ( 2 g/dL) and/or
haematocrit ( 10%) in OA patients
Risk factors
Odds
ratio 80% CI P value*
CRP (>1 mg/dL vs.  1 mg/dL) 2.27 1.46–3.53 0.0169
Positive H. pylori at
screening (yes vs. no)
1.54 1.07–2.22 0.1263
Age† (continuous variable) 1.17 1.04–1.32 0.0845
History of gastritis and GI
intolerance (yes vs. no)
1.55 1.06–2.28 0.1446
BMI‡ (continuous variable) 1.03 1.00–1.06 0.1762
* Significance taken to upper level (P < 0.20, 80% CI level) as
study was not designed for testing risk factors.
† Odds ratio estimate for every 5-year increase.
‡ Odds ratio estimate for every unit increase.
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developing clinically significant decreases in haemoglobin
( 2 g/dL) and/or haematocrit ( 10%) for these OA
patients (Table 2). Race, gender, prior PPI use, alcohol
consumption, history of upper GI complications, history
of lower GI disorders and history of anaemia were not
found to be predictive of clinically significant decreases
in haemoglobin.
Additional analysis was conducted to determine if ste-
roid use was associated with a haemoglobin drop. In the
RA population, steroid use was associated with a  2 g/dL
haemoglobin drop (11/403 patients without steroid use
vs. 17/307 patients with steroid use; P = 0.0569). No
patients in the OA population with steroid use had a
 2 g/dL haemoglobin drop.
DISCUSSION
In this post hoc analysis of the CONDOR trial, 64 OA
patients treated with celecoxib or diclofenac SR plus
omeprazole had a  2 g/dL decrease in haemoglobin
and/or  10% decrease in haematocrit with an observed
‘Clinically Significant Upper and Lower GI Event.’
Among the 15 risk factors studied in this analysis, the
risk factors found to be associated with blood loss in OA
patients included increasing age, baseline CRP levels,
H. pylori at screening, history of gastritis and GI intoler-
ance and increasing BMI. While the significance of BMI
as a risk factor was modest, this represents the first
information on BMI as a predictive factor for blood loss
throughout the GI tract in NSAID users. The reason for
that is unclear, but it may represent the known associa-
tion of obesity with more comorbidities.
Numerous risk factors previously have been identified
to be associated with bleeding in the upper GI tract
(prior ulcer disease, use of multiple or high-dose NSA-
IDs, increasing age, anticoagulant treatment and
H. pylori infection)11, 12 or lower GI tract (increasing age
and prior lower GI event) of NSAID users.14, 16 The cur-
rent analysis confirms these observations that increasing
age and H. pylori at screening were found to be predic-
tive of  2 g/dL decrease in haemoglobin due to either
confirmed or presumed GI blood loss. Helicobacter pylori
at screening and history of gastritis and GI intolerance
should in principle be linked to blood loss from the
upper GI tract and both should be within the same clini-
cal spectrum. However, upper GI complications were not
found to be an associated risk factor, likely due to their
infrequent occurrence in the trial.
Idiopathic anaemia has been linked to H. pylori infec-
tion in multiple studies.17 Although patients with active
H. pylori infection were not enrolled in the study, the
proportion of patients with a positive H. pylori infection
who underwent eradication before enrolment was high
(876/4484 or ~20%).1 Whether this population represents
one with a higher risk of developing a haemoglobin drop
due to blood loss from the GI tract—wherever the lesion
in the GI tract develops—when taking NSAIDs with
pre-existing iron deficiency or lower iron deposits, needs
to be proved, but they were clearly identified as suscepti-
ble to developing blood loss in this study.
History of gastritis and GI intolerance or dyspepsia
has been found to be linked to a higher risk or to be a
marker of gastroduodenal damage.18, 19 This is espe-
cially relevant in areas where H. pylori infection is com-
mon. Patients in this trial were recruited in countries
with high H. pylori infection rates and the presence of
H. pylori infection was one of the main exclusion crite-
ria. In any case, the current data cannot provide a clear
reason to explain why both H. pylori infection and GI
intolerance were identified as risk factors for haemo-
globin drops due to GI blood loss, and requires further
exploration. The CONDOR study design might have led
to missed lesions in these patients (erosions, small
ulcers) that could be responsible for the observed blood
loss, since GI investigations/endoscopies were not
always performed immediately after stopping the
NSAID. Upper GI tract lesions potentially explaining
haemoglobin drops do not exclude the presence of
other lesions in the small bowel. This could not be
demonstrated as the small bowel was not examined in
CONDOR trial.
C-reactive protein was found to be the risk factor with
the strongest association with the primary diagnosis.
There is a growing body of evidence suggesting that
development of OA is accompanied by inflammation,
and that high-sensitivity (hs) CRP is a sensitive marker
of systemic inflammation in these patients,20 which may
put them at a higher risk of developing GI adverse
events. Some previous studies have demonstrated that
elevated hs-CRP is associated with disease progression
and a higher incidence of disease symptoms in patients
with OA.21–24 Nevertheless, in the CONDOR trial data
were collected on CRP, not hs-CRP, and therefore we
cannot confirm whether this specific CRP marker was
the one actually associated with the outcome. In the cur-
rent analysis, baseline CRP levels of >1 mg/dL were
identified as a positive predictor of clinically significant
GI blood loss. Indeed, there is evidence that serum CRP
levels are associated with poor outcomes in patients with
GI bleeding. In patients hospitalised with upper and
lower GI bleeding, elevated serum CRP levels at hospital
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admission were associated with greater mortality.25
Although the current findings suggest CRP is a risk fac-
tor for clinically significant decreases in haemoglobin,
further studies are needed to determine the specific con-
tribution of CRP in OA disease pathogenesis.
Race, gender, prior PPI use, alcohol consumption and
history of anaemia were not found to be predictive of
clinically significant decreases in haemoglobin nor was
the history of upper GI complications. In the CONDOR
trial1 and in previous studies26, 27 where patients were
treated with celecoxib or NSAID plus PPI a similar
reduction in the number of upper GI complications was
observed between the two treatments. Therefore, as all
patients were treated with two equally effective treat-
ments for the prevention of upper GI complications, it
may explain why, in this trial, a history of previous
upper GI bleeding was not singled out as a risk factor
for GI blood loss.
We believe that the data presented in this post hoc
analysis of the CONDOR trial are relevant to the real-
life clinical situation facing many physicians prescribing
NSAIDs today. First, the data are determined from a
randomised clinical trial.1 The analysis focuses on clini-
cally significant blood loss (predefined as haemoglobin
drop of  2 g/dL and/or haematocrit drop of  10%)
adjudicated as having confirmed or presumed a GI aeti-
ology, as demonstrated by being included in the com-
posite primary end point for the CONDOR trial,
‘Clinically Significant Upper and/or Lower GI Events.’
An analysis of pooled studies with patient-reported out-
comes data showed those patients with haemoglobin
decreases of  2 g/dL were associated with no improve-
ment in function irrespective of treatment group.28 Fur-
thermore, the clinical validity of a fall in haemoglobin
levels of  2 g/dL has been confirmed by its inclusion
among the criteria for “major bleeding” by the Control
of Anticoagulation Subcommittee of the International
Society on Thrombosis and Haemostasis29 and it has
also been used as criteria for “major bleeding” in large
CV outcome clinical trials.30, 31 Secondly, the presence
of even low-normal haemoglobin values has been
shown to have a detrimental effect on clinical out-
comes, particularly in elderly patients. Anaemia result-
ing from significant reductions in haemoglobin is
associated with poorer physical performance, increased
disability, more hospitalisations, impaired quality of life
and a higher risk of CV events and overall mortality.32–
36 An analysis of pooled studies examining patient-
reported outcomes data showed that those arthritis
patients with haemoglobin decreases of  2 g/dL failed
to improve functional status irrespective of treatment
group.28
The limitations associated with this post hoc analysis
are the same as those described in the CONDOR trial.1
The main limitations included excluding aspirin users and
patients with a positive H. pylori status at screening, and
adjudicating presumed occult GI bleeding by exclusion,
rather than by direct confirmation of blood loss.1 A fur-
ther limitation included excluding the RA population.
Although this criterion reduced the confounding effect of
steroid use, the results cannot be extrapolated to patients
with RA. Another limitation is the collection of CRP mea-
surements rather than hs-CRP. Therefore, we could not
confirm whether this specific CRP marker was the one
actually associated with the outcome. In addition, as the
CONDOR trial was not designed for testing risk factors,
the significance could only be taken to the upper level of
P < 0.20 and an 80% CI level.
In conclusion, the results of this analysis suggest OA
patients with high GI risk should be considered for mon-
itoring for potential decreases in haemoglobin, particu-
larly in those with an increased age, BMI, history of
gastritis and GI intolerance and/or positive H. pylori sta-
tus, as this may affect their clinical management. This is
especially relevant for OA patients with CRP levels
>1 mg/dL. Based on these results, it appears to be clini-
cally relevant to evaluate the risk factors that may predict
decreases in haemoglobin levels in OA patients at parti-
cularly high GI risk, receiving treatment with NSAIDs.
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